Kalaris Therapeutics, Inc.

KLRS Nasdaq SEC CIK 1754068
Follow Kalaris Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$11M +7.3% vs same quarter last year
EPS, diluted −$0.46 +28.1% vs same quarter last year
Operating cash flow −$10.6M +6.9% vs same quarter last year
Operating income −$11.8M +7.3% vs same quarter last year
Net income by quarter
−$22M
−$10.2M
−$11.4M
−$11.9M
−$10M
−$10.9M
−$11.5M
−$11M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$200M−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$43.4M
FY24−$69.2M
FY23−$190.4M
FY22−$168.7M
FY21−$172M
FY20−$69.8M
FY19−$23.8M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$38.6M
FY24-
FY23-
FY22-
FY21−$106.3M
FY20−$61M
FY19−$20.5M
FY18-